JP2013535218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013535218A5 JP2013535218A5 JP2013523627A JP2013523627A JP2013535218A5 JP 2013535218 A5 JP2013535218 A5 JP 2013535218A5 JP 2013523627 A JP2013523627 A JP 2013523627A JP 2013523627 A JP2013523627 A JP 2013523627A JP 2013535218 A5 JP2013535218 A5 JP 2013535218A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cytotoxic
- dendritic cells
- immature dendritic
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 210000004443 dendritic cell Anatomy 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 229920000669 heparin Polymers 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 210000001616 monocyte Anatomy 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229960002897 heparin Drugs 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000012460 protein solution Substances 0.000 claims 2
- 238000001179 sorption measurement Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1013443.5 | 2010-08-11 | ||
| GBGB1013443.5A GB201013443D0 (en) | 2010-08-11 | 2010-08-11 | Compositions and methods for producing dendritic cells |
| PCT/EP2011/063867 WO2012020100A2 (en) | 2010-08-11 | 2011-08-11 | Compositions and methods for producing dendritic cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013535218A JP2013535218A (ja) | 2013-09-12 |
| JP2013535218A5 true JP2013535218A5 (enExample) | 2014-09-25 |
| JP6060077B2 JP6060077B2 (ja) | 2017-01-11 |
Family
ID=42931452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523627A Expired - Fee Related JP6060077B2 (ja) | 2010-08-11 | 2011-08-11 | 樹状細胞を産生するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9567567B2 (enExample) |
| EP (1) | EP2603582B1 (enExample) |
| JP (1) | JP6060077B2 (enExample) |
| KR (1) | KR20130103492A (enExample) |
| CN (1) | CN103201378B (enExample) |
| AU (1) | AU2011288416B2 (enExample) |
| BR (1) | BR112013003385A2 (enExample) |
| CA (1) | CA2807892A1 (enExample) |
| EA (1) | EA201390215A1 (enExample) |
| GB (1) | GB201013443D0 (enExample) |
| SG (1) | SG187839A1 (enExample) |
| WO (1) | WO2012020100A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102925412A (zh) * | 2012-11-19 | 2013-02-13 | 昆明理工大学附属医院 | 一种制备肿瘤特异性抗原致敏dc的方法 |
| JP2017507950A (ja) * | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
| US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| AU2016257997A1 (en) | 2015-05-05 | 2017-11-09 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| AU2016276947A1 (en) | 2015-06-11 | 2017-12-14 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| CN105039256A (zh) * | 2015-07-13 | 2015-11-11 | 中政道和（北京）生物科技有限公司 | 一种支气管镜下获取肿瘤组织进行树突细胞培养扩增方法 |
| CA3037882A1 (en) * | 2016-09-23 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same |
| CA3087418A1 (en) * | 2018-01-18 | 2019-07-25 | University Of South Florida | Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases |
| BR112021000620A2 (pt) * | 2018-07-15 | 2021-04-20 | Enochian BioPharma, Inc. | métodos e composições com uso de células dendríticas recombinantes para terapia contra câncer |
| US12282027B2 (en) | 2021-02-19 | 2025-04-22 | University Of South Florida | High-throughput NMR approach for in-membrane protein ligand screening |
| WO2025076303A1 (en) * | 2023-10-05 | 2025-04-10 | Amgen Inc. | Major histocompatibility complex (mhc)-associated peptide proteomics (mapps) assay for immunogenicity risk assessment of biotherapeutic attributes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9617058D0 (en) | 1996-08-14 | 1996-09-25 | Sandoz Ltd | Organic compounds |
| US6458585B1 (en) * | 1996-08-14 | 2002-10-01 | Nexell Therapeutics Inc. | Cytokine-free culture of dendritic cells |
| AUPO388396A0 (en) * | 1996-11-27 | 1996-12-19 | Ludwig Institute For Cancer Research | Cellular adjuvant |
| JP2005515192A (ja) * | 2001-11-29 | 2005-05-26 | ダンドリット バイオテック アクティーゼルスカブ | ヒト又は動物において免疫応答を誘導するための医薬組成物 |
| US20060216269A1 (en) * | 2004-09-17 | 2006-09-28 | Kenichiro Hasumi | Dendritic cell tumor injection (DCTI) therapy |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| JP5279063B2 (ja) | 2007-05-25 | 2013-09-04 | 国立大学法人愛媛大学 | Ｈｌａ−ａ２拘束性抗原ペプチドおよびその用途 |
| JP2009013166A (ja) | 2007-06-04 | 2009-01-22 | Osaka Prefecture Univ | 腫瘍治療用組成物およびその応用 |
-
2010
- 2010-08-11 GB GBGB1013443.5A patent/GB201013443D0/en not_active Ceased
-
2011
- 2011-08-11 EP EP11749387.4A patent/EP2603582B1/en not_active Not-in-force
- 2011-08-11 CA CA2807892A patent/CA2807892A1/en not_active Abandoned
- 2011-08-11 CN CN201180046061.6A patent/CN103201378B/zh not_active Expired - Fee Related
- 2011-08-11 EA EA201390215A patent/EA201390215A1/ru unknown
- 2011-08-11 AU AU2011288416A patent/AU2011288416B2/en not_active Ceased
- 2011-08-11 BR BR112013003385A patent/BR112013003385A2/pt not_active IP Right Cessation
- 2011-08-11 SG SG2013010855A patent/SG187839A1/en unknown
- 2011-08-11 WO PCT/EP2011/063867 patent/WO2012020100A2/en not_active Ceased
- 2011-08-11 KR KR1020137004865A patent/KR20130103492A/ko not_active Ceased
- 2011-08-11 US US13/816,359 patent/US9567567B2/en not_active Expired - Fee Related
- 2011-08-11 JP JP2013523627A patent/JP6060077B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013535218A5 (enExample) | ||
| Lee et al. | Dendritic cell vaccines: a shift from conventional approach to new generations | |
| JP2010514455A5 (enExample) | ||
| Matsuo et al. | Recent progress in dendritic cell-based cancer immunotherapy | |
| Ning et al. | β‐glucan restores tumor‐educated dendritic cell maturation to enhance antitumor immune responses | |
| Lin et al. | Chitosan as an adjuvant-like substrate for dendritic cell culture to enhance antitumor effects | |
| Liu et al. | Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK) | |
| JP2009542714A (ja) | ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 | |
| US20120128656A1 (en) | Vaccine compositions and methods | |
| Hansen et al. | Cellular based cancer vaccines: type 1 polarization of dendritic cells | |
| Su et al. | Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models | |
| Hradilova et al. | Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy | |
| CN107488235A (zh) | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 | |
| Meng et al. | Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy | |
| Shan et al. | Functional modulation of the pathway between dendritic cells (DCs) and CD4+ T cells by the neuropeptide: methionine enkephalin (MENK) | |
| JP2017025066A (ja) | 高静水圧によって死滅させた腫瘍細胞および樹状細胞を用いた活性細胞癌免疫療法のための手段および方法 | |
| CN105031641A (zh) | 基于dc的hcv病毒表位疫苗及其制备方法 | |
| Huang et al. | Anti-tumor efficacy of an adjuvant built-in nanovaccine based on ubiquitinated proteins from tumor cells | |
| JP2013523886A5 (enExample) | ||
| JP2012504948A5 (enExample) | ||
| CN111662870A (zh) | 卡介菌多糖核酸在cik细胞体外培养及制备肿瘤药物中的应用 | |
| JP2010265327A (ja) | 癌抗原非特異的な標的化ｔ細胞の製造方法及び医薬 | |
| Pizzurro et al. | Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine | |
| Hiramoto et al. | Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-γ and interleukin-12 | |
| Smith et al. | Immunotherapy in cancer treatment |